Astellas : Izervay Monthly Or Every Other Month Reduced GA Lesion Growth Through 2 Years
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Astellas Pharma Inc. (ALPMY, ALPMY) announced results from the GATHER2 Phase 3 clinical trial, demonstrating Izervay (avacincaptad pegol intravitreal solution) continued to reduce the rate of geographic atrophy lesion growth for both every month or EM and every-other-
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-611491884-eab74d4b61364ec987b80bff4c516a23.jpg "5 Financial Considerations for Later-in-Life Marriage")